Gurobi Helps Software Companies Successfully Integrate Optimization Into Their Solutions
15.9.2022 03:50:00 EEST | Business Wire | Press release
Gurobi Optimization, LLC, creator of the world’s fastest mathematical optimization solver, has launched a new program to help independent software vendors (ISVs) tackle customers’ increasingly complex business challenges and keep up with ever-evolving customer needs.
While 85% of Fortune 500 companies use mathematical optimization, smaller startups and scaleups in the tech world are catching on to the value an industry-leading solver like Gurobi can bring to their software solutions. In fact, 70% of top global tech companies now use Gurobi.
Gurobi wants to be more than just a supplier to the ISVs that utilize its mathematical optimization technology; it wants to be a partner. That is the motivation behind the new Gurobi Partner Accelerator Program.
The 36-month program aims to create joint value between Gurobi and solution providers by setting and achieving shared business, product, and revenue goals.
“It’s not just a supplier relationship. We see it as a partnership. We want to support these companies and go hand-in-hand with them. If they grow, we grow together,” explained Jan Schwarzkopf, Gurobi Account Manager - Europe Ecosystem.
The Gurobi Partner Accelerator Program
Gurobi is offering a partnership with companies in the final stages of developing a software solution that utilizes its optimization technology. Companies will receive ongoing technical support, which is a critical asset in these final development stages.
In addition to technical support, partner companies will receive business and marketing support to accelerate their product’s time to market and maximize sales once launched.
This program is not just for companies in the development stage, though. ISVs that utilize Gurobi for products already on the market will also be eligible. The program’s ongoing technical and business support is essential for any company that wants to enhance its product to stay ahead in the highly competitive software market.
Benefits of the Program
By participating in the program, ISVs will receive the following:
- Easy Access to Gurobi’s Technology - Solution partners will receive access to Gurobi’s best-in-class technology, including a product license based on their business needs.
- Ongoing Sales and Marketing Support - The program includes guidance on sales and marketing strategies. Gurobi will work hand-in-hand with partners to advise on the best way to market their product and maximize sales once launched.
- Quarterly Engagement for Business Strategy - Gurobi will meet at least quarterly with solution partners to assist with high-level business strategy. Partners will get expert guidance on formulating and executing business goals.
Who Should Consider This Program?
The Gurobi Partner Accelerator Program is not limited to ISVs currently using Gurobi’s technology for their software solutions. Companies using an open-source solver or competitive commercial solver are also encouraged to consider the program.
For those using either an open-source or commercial solver, Gurobi poses the following questions:
- Are you or your end customers satisfied with the current performance of your software application?
- Does your relationship with your current optimization technology supplier support your business growth?
If the answer to one or both of these questions is no, the Gurobi Partner Accelerator Program might be the solution.
The software industry is getting more competitive every year, and ISVs need to ensure their solutions use every advantage available. The Gurobi Partner Accelerator Program is an excellent opportunity to access leading optimization solver technology, as well as hands-on support from experts who want their partners to succeed with optimization.
To learn more about the program, please visit https://www.gurobi.com/gurobi-alliance/gurobi-partner-accelerator-program/.
About Gurobi Optimization
With Gurobi’s decision intelligence technology, you can make optimal business decisions in seconds. From workforce scheduling, portfolio management, and marketing optimization, to supply chain design, and everything in between, Gurobi identifies your optimal solution, out of trillions of possibilities.
As the leader in decision intelligence, Gurobi delivers easy-to-integrate, full-featured software and best-in-class support, with an industry-leading 98.5% customer satisfaction rating.
Founded in 2008, Gurobi has operations across the Americas, Europe, and Asia. Over 2,500 global customers across 40+ industries run on Gurobi, including SAP, Air France, and the National Football League, as well as half of the Fortune 10 and 70% of top global tech companies. For more information, please visit https://www.gurobi.com/ or call +1 713 871 9341.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005558/en/
Contact information
Nell-Marie Colman
(540) 952 9719
Gurobi Optimization
colman@gurobi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom